Kmk Pharma Consulting Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 47.41%
- Profit Growth 16.60%
- Ebitda 84.52%
- Net Worth 62.99%
- Total Assets -17.36%
About Kmk Pharma Consulting
Kmk Pharma Consulting Private Limited (KPCPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 October 2018 (Six years and four months 25 days old ). Its registered office is in Vadodara, Gujarat, India.
The Corporate was formerly known as Kmk Computech Private Limited. The Company is engaged in the Information Technology Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mikhail Karbachinskiy and Esha Patel serve as directors at the Company.
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U72500GJ2018PTC104593
- Company No.
104593
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Information Technology
Who are the key members and board of directors at Kmk Pharma Consulting?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mikhail Karbachinskiy  | Director | 04-Oct-2018 | Current |
Esha Patel  | Director | 04-Oct-2018 | Current |
Financial Performance of Kmk Pharma Consulting.
Kmk Pharma Consulting Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 47.41% increase. The company also saw a substantial improvement in profitability, with a 16.6% increase in profit. The company's net worth Soared by an impressive increase of 62.99%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kmk Pharma Consulting?
Unlock access to Kmk Pharma Consulting's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kmk Pharma Consulting?
Kmk Pharma Consulting has a workforce of 91 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kmk Pharma Consulting, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kmk Pharma Consulting's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.